SCM
JAZZ icon

Segantii Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Segantii Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,300
Closed -$3.27M – 159
2023
Q3 		$3.27M Buy
+25,300
New +$3.37M 0.12% 74

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Segantii Capital Management's JAZZ Position: Q4 2023 in Review

Segantii Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 25,300 shares — an estimated $3.27M sold.

Segantii Capital Management first reported a position in JAZZ in Q3 2023 and held it in 1 quarter. The position peaked at $3.27M in Q3 2023. 499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Segantii Capital Management reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Segantii Capital Management sold 25,300 Jazz Pharmaceuticals shares in Q4 2023, an estimated $3.27M.
  • Segantii Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Segantii Capital Management's Jazz Pharmaceuticals position peaked at $3.27M in Q3 2023.
  • 499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Segantii Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.